An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...
Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...
Findings support model in which accelerated biological aging of mammary epithelia may underpin breast cancer susceptibility ...
TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...
PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for ...
A recent study published in Cell Reports Medicine has identified distinct microbial signatures within the oral cavity and gut ...
New cfDNA test enables multicancer detection with high accuracy, offering a cost effective approach for early diagnosis and ...
TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...
The United States Food and Drug Administration (FDA) issued guidance on its “Breakthrough Devices Program” in 2023. The ...
Predicting the uptake of free cancer screening services in rural India using machine learning tools.
This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results